Morningstar Investor users sign in here.

Stocks

Waiving vaccine IP doesn't affect market assessment: Morningstar

We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.

Mentioned: Moderna Inc (MRNA), BioNTech SE (BNTX), Pfizer Inc (PFE)


We're not making changes to our fair value estimates or moat ratings for COVID-19 vaccine firms following the May 5 announcement that the Biden administration supports a proposed waiver on intellectual property protection for COVID-19 vaccines.

The proposal to waive patent rights during the pandemic was initially made to the World Trade Organization by India and South Africa in October. With the pandemic raging in India and Brazil, calls to support this proposal have strengthened, and US, Europe, and UK opposition has become a potential political liability. It could take months to finalise the proposal, and Europe and UK have yet to support the waiver.

Beyond IP, we see huge skill and supply-related barriers to designing and building efficient mRNA manufacturing at scale outside of global leaders Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA), and their contract manufacturing networks. Moderna disclosed in October that it would not enforce its COVID-19 patents during the pandemic but has not seen any signs of copycat production globally, which we think supports the idea barriers to production beyond IP. Using raw materials in short supply (like lipids) for riskier efforts at new facilities rather than for established networks could result in reduced global supply in 2021 and 2022.

After incorporating updates from Moderna and Pfizer with first-quarter earnings, we have raised our forecast for COVID-19 vaccine sales to $70 billion in 2021 (from $67 billion as of April 22). Beyond 2021, both Moderna and Pfizer/BioNTech are negotiating new contracts, and they remain best positioned to develop the first vaccines against new variants.

Moderna has released the first data for a third dose with its mRNA-1273.351 variant vaccine that imply stronger and more consistent protection across variants, and Pfizer expects data from its own variant vaccine in July. Pfizer also noted that future variant vaccine updates may only need a lead time until regulatory authorisation of roughly 100 days.

Morningstar ratings

Vaccine producers

Source: Morningstar



© 2023 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.

More from Morningstar

Despite rally this A-REIT remains undervalued
Stocks

Despite rally this A-REIT remains undervalued

While attractive from a valuation standpoint we do not believe this A-REIT warrants a moat and is highly leveraged.
We advise waiting for a pullback before investing in the world's biggest company
Stocks

We advise waiting for a pullback before investing in the world's biggest company

We’ve raised our fair value estimate and sales forecast, but still see the stock as rich.
7 charts on the AI stock boom one year after ChatGPT’s launch
Stocks

7 charts on the AI stock boom one year after ChatGPT’s launch

These stocks and the key trends behind them are critical for understanding the AI investment landscape.
Why Berkshire Hathaway’s success will continue after Charlie Munger ... and Warren Buffett
Stocks

Why Berkshire Hathaway’s success will continue after Charlie Munger ... and Warren Buffett

Munger’s passing is a spiritual loss for the company.
Morningstar initiates coverage on 3 new shares
Stocks

Morningstar initiates coverage on 3 new shares

There are 2 undervalued names as part of our new coverage. 
3 shares for income investors
Stocks

3 shares for income investors

A dividend screen is a jumping off point for further research.